[Endocrinal and chemotherapy of the metastasising mastocarcinoma (author's transl)].
Treatment of the metastasising mastocarcinoma is based on endocrinal and cytostatic treatment methods arranged systematically in parallel and in series. With endocrinal therapy alone, remission rates of around 30% are achieved, whereas with polychemotherapy the remission rates are 50 to 60%. For a large proportion of the patients, the systematic application of both methods leads to definite increase in life expectancy at a tolerable quality of life level. The determination of steroid hormone receptors in the tumorous tissue allows better selection of the patients and hence better on-target therapy.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008593:Menopause; D009362:Neoplasm Metastasis; D011379:Prognosis; D013997:Time Factors
D000970:Antineoplastic Agents
Endokrine und Chemotherapie des metastasierenden Mammakarzinoms.